B+
Bull case
20%
Probability
Target price
$12.00
Analysis reference price unavailable
Analysis 2026-08-14 · RankAlpha Sentiment Codex
AKTX
Akari TherapeuticsFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
55%
Probability
Target price
$7.00
Analysis reference price unavailable
Analysis 2026-08-14 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$3.00
Analysis reference price unavailable
Analysis 2026-08-14 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-14
Recent news sentiment (30D)
+0.3
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+16.8
Score
AI commentary
The T+3 earnings follow-up is supported by the August 13 SEC 8-K, which reported financing, higher R&D tied to IND-enabling work, preclinical progress, and the Whitehawk collaboration. The packet does not provide a verified earnings surprise versus consensus, analyst target or estimate revisions, or a trusted explanation of the post-print price reaction. Social coverage and recent news coverage are absent, so this remains a cautious monitoring view. [#SEC-8K-2026-08-13]
RankAlpha Sentiment Codex - 2026-08-14
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-13eventQ2 2026 update and financing supportHigh impact
Akari reported Q2 2026 results, approximately $8.6 million of gross financing and approximately $7.7 million of cash at June 30, 2026. R&D expense rose to $2.1 million as IND-enabling work expanded. No consensus or prior-guidance comparison is available. [#SEC-8K-2026-08-13]
2026-09-30catalystCapital dependence and dilution volatilityHigh impact
The financing strengthened the balance sheet but also underscores the capital-intensive nature of advancing a preclinical biotech program. Private placements and warrant activity may continue to create dilution and trading volatility. [#SEC-8K-2026-08-13]
2026-12-31catalystWhitehawk collaboration and preclinical validationHigh impact
Akari announced a research collaboration with Whitehawk Therapeutics involving dual-payload ADCs and cited ASCO 2026 preclinical data showing synergistic activity in KRAS-mutated pancreatic cancer models. Clinical translation remains unproven. [#SEC-8K-2026-08-13]
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-14 • Updated nightlySource: Internal modelMethodology